[{"id":"0fed4813-2327-42f4-8f7e-67b0a8ca6e06","acronym":"","url":"https://clinicaltrials.gov/study/NCT00679354","created_at":"2021-01-18T02:32:24.165Z","updated_at":"2024-07-02T16:37:08.366Z","phase":"Phase 2","brief_title":"Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy","source_id_and_acronym":"NCT00679354","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABCB1 • ABCG2","pipe":"","alterations":" ","tags":["ABCB1 • ABCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cilcane (cilengitide)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2008","start_date":" 06/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 07/01/2011","study_completion_date":" 07/01/2011","last_update_posted":"2018-08-01"},{"id":"b5a55c36-5953-4427-91dd-2abf2cd086a6","acronym":"CORE","url":"https://clinicaltrials.gov/study/NCT00813943","created_at":"2021-07-05T16:06:11.066Z","updated_at":"2025-02-25T15:58:50.875Z","phase":"Phase 2","brief_title":"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status","source_id_and_acronym":"NCT00813943 - CORE","lead_sponsor":"EMD Serono","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Cilcane (cilengitide)"],"overall_status":"Completed","enrollment":" Enrollment 265","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":" Completion: 08/01/2013","study_completion_date":" 08/01/2013","last_update_posted":"2017-01-30"},{"id":"173cfc37-36d1-4216-b1f0-deabd2fac618","acronym":"CERTO","url":"https://clinicaltrials.gov/study/NCT00842712","created_at":"2021-01-18T03:12:28.287Z","updated_at":"2025-02-25T14:48:21.278Z","phase":"Phase 2","brief_title":"Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT00842712 - CERTO","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" EGFR • KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • EGFR expression","tags":["EGFR • KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • gemcitabine • vinorelbine tartrate • Cilcane (cilengitide)"],"overall_status":"Completed","enrollment":" Enrollment 232","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2017-01-13"}]